Topline information anticipated to be reported in Q1 2023
June 2, 2022
CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a analysis and clinical-stage biomaterials and biotechnology firm with a concentrate on the therapy of spinal twine accidents, immediately introduced that it has accomplished enrollment within the INSPIRE 2.0 Research for sufferers with acute spinal twine harm. The 20-patient research is a randomized, managed trial that includes 10 topics in every research arm, designed to reinforce the prevailing scientific proof for the Neuro-Spinal Scaffold™ from the Firm’s INSPIRE 1.0 research.
“Reaching full enrollment in our INSPIRE 2.0 research is a big development in our analysis and growth efforts in direction of a possible therapy for spinal twine harm,” stated Richard Toselli, M.D., InVivo’s President and Chief Government Officer. “We’re grateful to the research contributors, in addition to the clinicians, investigators, and employees who’ve labored relentlessly to make this potential, and naturally to our crew at InVivo. We’re very excited to be persevering with in direction of our objective of serving this affected person inhabitants and anticipate to current topline information from the research in Q1 of 2023.”
Kee Kim, M.D., Professor and Chief of Spinal Neurosurgery at UC Davis, Sacramento, CA, and a Principal Investigator within the INSPIRE 2.0 Research, said “Finishing affected person enrollment within the INSPIRE 2.0 Research is a serious milestone for the spinal twine harm neighborhood, and I’m happy to have had the chance to assist enhance potential therapy choices for this underserved affected person inhabitants.”
For extra particulars on the Firm’s INSPIRE 2.0 Research, please go to this hyperlink.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a analysis and clinical-stage biomaterials and biotechnology firm with a concentrate on therapy of spinal twine accidents. The corporate was based in 2005 with proprietary know-how co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Know-how, and Joseph P. Vacanti, M.D., who then was at Boston Youngsters’s Hospital and who now could be affiliated with Massachusetts Common Hospital. The publicly traded firm is headquartered in Cambridge, MA. For extra particulars, go to www.invivotherapeutics.com.
Secure Harbor Assertion
Any statements contained on this press launch that don’t describe historic details might represent forward-looking statements inside the that means of the federal securities legal guidelines. These statements will be recognized by phrases comparable to “consider,” “anticipate,” “intend,” “estimate,” “will,” “might,” “ought to,” “anticipate” and comparable expressions, and embrace statements concerning the corporate’s expectation concerning the timing for the announcement of topline information and skill to serve the spinal twine harm affected person inhabitants. Any forward-looking statements contained herein are based mostly on present expectations and are topic to various dangers and uncertainties. Components that might trigger precise future outcomes to vary materially from present expectations embrace, however aren’t restricted to, dangers and uncertainties referring to: the corporate’s potential to acquire extra funding to help the continued scientific and potential commercialization program for the investigational Neuro-Spinal Scaffold™, the numerous interpretation of scientific information, the timing, value and expense of regulatory filings, the potential for regulatory authorities granting or delaying approval for our Neuro-Spinal Scaffold, and different dangers related to the corporate’s enterprise, analysis, product growth, regulatory approval, advertising and distribution plans and techniques recognized and described in additional element within the firm’s Quarterly Report on Kind 10-Q for the quarter ended March 31, 2022, and in different filings that the corporate might make with the Securities and Change Fee sooner or later. The corporate doesn’t undertake to replace these forward-looking statements.
Contacts
Traders:
Bret Shapiro, Managing Associate
CORE IR
brets@coreir.com
(516) 222-2560
Media:
Gina Nugent
Ten Bridge Communications
gina@tenbridgecommunications.com
617-460-3579
Discussion about this post